← 治験一覧に戻る
肝細胞癌患者を対象としたレンバチニブとペムブロリズマブの併用療法に関する臨床試験
基本情報
- NCT ID
- NCT03006926
- ステータス
- 完了
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 104
- 治験依頼者名
- Eisai Inc.
概要
This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria In Solid Tumors (mRECIST) for HCC and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on independent imaging review (IIR).
対象疾患
Hepatocellular Carcinoma
介入
lenvatinib(DRUG)
pembrolizumab (200 mg)(DRUG)